Sanghoon Lee

发表

Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers

Jeffrey T. Chang, Jason B. White, G. Mills, 2022, npj Breast Cancer.

Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options

G. Mills, Z. Ju, Yiling Lu, 2019, Oncotarget.

Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer

P. A. Futreal, K. Baggerly, G. Mills, 2020, Cell reports.

im n algorithm for direct causal learning of influences on patient utcomes

Xia Jiang, Sanghoon Lee, handramouli Rathnam, 2017 .

An integral genomic signature approach for tailored cancer therapy using genome-wide sequencing data

Han Zhang, G. Tang, Yue Wang, 2022, Nature Communications.

Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer

A. Sood, R. Coleman, H. Alila, 2020, Molecular Cancer Therapeutics.

Targeting the ALK–CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex

G. Hortobagyi, M. Hung, A. Sood, 2022, Nature Cancer.

Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics

Prahlad T. Ram, P. A. Futreal, Jun Yao, 2022, JAMA network open.

Molecular Profiles of Serum-Derived Extracellular Vesicles in High-Grade Serous Ovarian Cancer

P. A. Futreal, Erika J. Thompson, A. Jazaeri, 2022, Cancers.

Robust meta-analysis shows that glioma transcriptional subtyping complements traditional approaches

Stephen R. Piccolo, K. Allen-Brady, Sanghoon Lee, 2014, Cellular Oncology.

Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer

G. Mills, A. Jazaeri, A. Sood, 2021, Clinical Cancer Research.

Modeling miRNA-mRNA interactions that cause phenotypic abnormality in breast cancer patients

Xia Jiang, Xia Jiang, Sanghoon Lee, 2017, PloS one.

Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance

R. Schiff, Ling Lin, Yiheng Hu, 2020, bioRxiv.

Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers

Jeffrey T. Chang, Jason B. White, Fei Yang, 2022, npj Breast Cancer.

Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.

G. Mills, Z. Ju, M. Birrer, 2019, Gynecologic oncology.

Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype

Prahlad T. Ram, P. Ram, A. Sood, 2021, Cell reports.

Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer

M. Ellis, S. Hilsenbeck, R. Schiff, 2021, Clinical Cancer Research.

A Novel Neoplastic Fusion Transcript, RAD51AP1-DYRK4, Confers Sensitivity to the MEK Inhibitor Trametinib in Aggressive Breast Cancers

Yiheng Hu, Ying Tan, Xiao-Song Wang, 2020, Clinical Cancer Research.

Universal concept signature analysis: genome-wide quantification of new biological and pathological functions of genes and pathways

Pelle Hall, Sanghoon Lee, Xu Chi, 2019, Briefings Bioinform..

Landscape analysis of adjacent gene rearrangements reveals BCL2L14–ETV6 gene fusions in more aggressive triple-negative breast cancer

R. Bhargava, M. Lewis, Yiheng Hu, 2020, Proceedings of the National Academy of Sciences.

An integral genomic signature approach for tailored cancer targeted therapy using genome-wide sequencing data

G. Tang, Yue Wang, Xiaosong Wang, 2021, bioRxiv.

CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance

Prahlad T. Ram, P. Ram, A. Sood, 2021, Cell reports.

Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy.

G. Mills, Yongsheng Li, Z. Ju, 2019, Cancer cell.

Spatially resolved transcriptomics of high-grade serous ovarian carcinoma

A. Sood, Patricia D. Castro, Jianhua Zhang, 2022, iScience.

Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups

P. A. Futreal, A. Sood, Jianhua Zhang, 2021, iScience.

Molecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer

P. A. Futreal, T. Conrads, A. Sood, 2022, Cancers.

Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer

Jin Heon Jeon, A. Sood, L. Eberlin, 2023, iScience.

An algorithm for direct causal learning of influences on patient outcomes

Sanghoon Lee, Xia Jiang, Chandramouli Rathnam, 2017, Artif. Intell. Medicine.

Clinical implications of tumor‐based next‐generation sequencing in high‐grade epithelial ovarian cancer

A. Jazaeri, Z. Ju, A. Sood, 2023, Cancer.

A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy

A. Sood, A. Malpica, Jinsong Liu, 2021, Cancers.

Tumor immune microenvironment changes by multiplex immunofluorescence staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a hereditary BRCA mutation.

Jeffrey T. Chang, Fei Yang, Yiling Lu, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial.

A. Jazaeri, J. Celestino, S. Westin, 2024, Med.